ArticleMetabolic brain disease2026
The SIRT-1/Nrf-2/HO-1 antioxidant defense axis in adult attention-deficit/hyperactivity disorder.
Article in Metabolic brain disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Attention-Deficit/Hyperactivity Disorder (ADHD) frequently persists into adulthood and is associated with substantial functional impairment. Beyond classical neurotransmitter dysregulation, increasing evidence points to oxidative stress and impaired cellular defense mechanisms as key contributors to ADHD pathophysiology. However, data on upstream redox-regulatory pathways in adult ADHD remain limited. To evaluate serum tumor necrosis factor-alpha (TNF-α), heme oxygenase-1 (HO-1), nuclear factor erythroid 2–related factor 2 (Nrf-2), and sirtuin-1 (SIRT-1) levels in adults with ADHD and to examine their associations with symptom severity and clinical features. This cross-sectional study included 60 adults diagnosed with ADHD and 60 age- and sex-matched healthy controls. ADHD diagnosis was established using the Structured Clinical Interview for DSM-5 Clinician Version (SCID-5/CV) and the DIVA 2.0 diagnostic interview. Symptom severity was assessed using the Adult ADHD Self-Report Scale (ASRS). Serum TNF-α, HO-1, Nrf-2, and SIRT-1 levels, along with routine laboratory parameters, were measured and compared between groups. Associations between biomarkers and symptom severity were analyzed. Serum SIRT-1 (9.36 ± 9.62 vs. 18.52 ± 14.90, p < 0.001), Nrf-2 (11.18 ± 10.53 vs. 22.05 ± 17.44, p < 0.001), and HO-1 (0.86 ± 0.95 vs. 1.89 ± 1.65, p < 0.001) levels were significantly lower in adults with ADHD compared to controls, whereas TNF-α levels did not differ between groups (7.49 ± 2.15 vs. 7.78 ± 2.06, p = 0.439). CRP levels were modestly higher (3.50 ± 1.59 vs. 2.86 ± 1.68, p = 0.036), and ferritin levels were lower in the ADHD group (49.78 ± 46.68 vs. 71.54 ± 63.80, p = 0.035). SIRT-1 (r = − 0.430, p = 0.001), Nrf-2 (r = − 0.446, p < 0.001), and HO-1 (r = − 0.424, p = 0.001) levels were negatively correlated with ADHD symptom severity. ROC analysis demonstrated moderate discriminatory performance for HO-1 (AUC = 0.797), Nrf-2 (AUC = 0.756), and SIRT-1 (AUC = 0.753). Adult ADHD was associated with reduced serum SIRT-1, Nrf-2, and HO-1 levels, pointing to alterations in redox-regulatory mechanisms. TNF-α did not differ between groups; however, broader inflammatory pathways were not comprehensively assessed. These findings support further research on oxidative stress–related regulation and its potential value for biomarker-informed clinical strategies in adult ADHD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.